Newspaper Advertisement for giving notice for the purpose of transfer of unclaimed dividend and corresponding equity shares of the Company to IEPFA.
Annual Secretraial Compliance Report for the financial year ended 31st March, 2026.
The Company has fixed Friday, 28th August, 2026, as the Record date for the Payment of Dividend for the Financial Year 2025-26 as well as cut-off date for Remote e-voting and e-voting during the 41st AGM.
Newspaper Publication for standalone Audited financial results for the quarter and financial year ended on 31st March, 2026.
The Board of Director of the Company recommeded a dividend of Rs.20.70 (207%) per equity share of Rs.10/- each on 4413300 equity shares of the Company for the financial year 2025-26, Subject to the approval of the menbers it the ensuing 41st AGM of the Company.
Re-appointment of Whole Time Director and CFO of the Company, subject to the approval of the members at the ensuing 41st Annual General meeting of the Company.
Standalone audited financial reults of the Company for the quarter and financial year ended on 31st March, 2026.
Outcome of Board Meeting Held on 05th May, 2026.
the audited results for the quarter and financial year ended on 31st March, 2026 and to consider recommendation of dividend, if any.
Pursuant to SEBI Circular dated 10th August, 2021, we hereby confirm that, for the financial year ended 31st March, 2026, Jenburkt pharmaceuticals Limited is "not a large corporate" as per applicability criteria mentioned in clause 2.11 of chapter XII therein.